SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, announced that it has obtained authorization to use eight trademarks within the European Union, including SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based low-cost multi-cancer early detection test), LungCanSeek® (blood-based lung cancer early detection test), SeekInCure® (blood-based pan-cancer recurrence monitoring test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (leukemia molecular karyotyping test), PanCanSeek® (pan-cancer therapeutics guidance test), and PetCanSeek® (pan-cancer early detection test for dogs). These acquisitions strengthen SeekIn Inc.'s intellectual property portfolio and open new avenues for the company to expand its reach and enhance its services within the European Union.